1. Decree n° 2012-1116, October 2, 2012, defining the health economics missions of the High Health Authority. French Republic Offical Gazette n° 0231, October 4 2012, page 15222, text n° 8. https://www.legifrance.gouv.fr/.
2. Decision n°2013.0111/DC/SEESP, September 18, 2013: Collge of the High Health Authority relative to the significiant impact on expenditures for the National Sickness Fund triggering the need for an economic assessment of health products claiming an improvement/expected of Medical Serivce Rendered of I, II or III. https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-09/c_2013_0111_definition_impact_significatif.pdf.
3. Haute Autorité de Santé (HAS). Choices in methods for economic evaluation. Department of Economics and Public Health Assessment. Haute Autorité de Santé; Oct 2012. https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf.
4. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57–66.
5. Costet N, Le Galès C, Buron C, Kinkor F, Mesbath M, et al. French cross-cultural adaptation of the Health Utilities Indexes mark 2 (HUI2) and 3 (HUI3) classification systems. Qual Life Res. 1998;7:245–56.